Inhal Pharma key facts
- Developer of a dry powder inhalation platform designed to advance formulation development, inhaler design, and inhaled drug manufacturing.
- It has raised $29.5M.
- Notable investors include Beijing State-owned Capital Operation and Management, Shun Xi Fund, Saiying Capital, Zhangzhou Pien Tze Huang Investment Management, Ascentage Pharma — 13 tracked in total.
- Status: Privately Held (backing).
Who backs Inhal Pharma
13+Membership and data by Private Market View
- ·The complete investor list: 13 names
- ·Watch Inhal Pharma: the Monday email on marks, rounds and moves
Inhal Pharma funding rounds
No funding rounds for Inhal Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Inhal Pharma investors
13 investors are on record for Inhal Pharma, including Beijing State-owned Capital Operation and Management, Shun Xi Fund, Saiying Capital and Zhangzhou Pien Tze Huang Investment Management.
About Inhal Pharma
Developer of a dry powder inhalation platform designed to advance formulation development, inhaler design, and inhaled drug manufacturing. The company offers integrated development capabilities, a portfolio of inhaled health products, generic dry powder inhalers, and emerging inhaled therapeutics, enabling patients with respiratory and systemic conditions to access practical and effective inhaled treatments.
- Sector
- Healthcare
- HQ
- Ningbo City, China
- Founded
- 2020
- Employees
- 80
- Website
- inhalpharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Inhal Pharma doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.